Gary L. Johnson

Gary L. Johnson is an American scientist and Professor recognized for his work with oncogenes and stem cells in the fields of molecular pharmacology and cancer cell biology. His other research interests include signaling networks controlling cell function and disease and the behavior of the kinome en masse in cancer.

Johnson is a past Kenan Distinguished Professor, chair of the UNC Chapel Hill Department of Pharmacology, and a member of the UNC Lineberger Comprehensive Cancer Center. Provided by Wikipedia
Showing 1 - 17 results of 17 for search 'Gary L. Johnson', query time: 0.07s Refine Results
  1. 1
    Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer

    Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer by Samantha M. Bevill, Jon S. Zawistowski, Gary L. Johnson

    Published 2017-11-01
    Get full text
    Article
  2. 2
    DEVDase detection in intact apoptotic cells using the cell permeant fluorogenic substrate, (z-DEVD)2-cresyl violet

    DEVDase detection in intact apoptotic cells using the cell permeant fluorogenic substrate, (z-DEVD)2-cresyl violet by Brian W. Lee, Gary L. Johnson, Sally A. Hed, Zbigniew Darzynkiewicz, Jamil W. Talhouk, Sanjiv Mehrotra

    Published 2003-11-01
    Get full text
    Article
  3. 3
    Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate.

    Defining the functional domain of programmed cell death 10 through its interactions with phosphatidylinositol-3,4,5-trisphosphate. by Christopher F Dibble, Jeremy A Horst, Michael H Malone, Kun Park, Brenda Temple, Holly Cheeseman, Justin R Barbaro, Gary L Johnson, Sompop Bencharit

    Published 2010-07-01
    Get full text
    Article
  4. 4
    Far away from the lamppost.

    Far away from the lamppost. by Tudor I Oprea, Lily Jan, Gary L Johnson, Bryan L Roth, Avi Ma'ayan, Stephan Schürer, Brian K Shoichet, Larry A Sklar, Michael T McManus

    Published 2018-12-01
    Get full text
    Article
  5. 5
    SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2

    SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2 by Gaurav A. Mehta, Steven P. Angus, Christen A. Khella, Kevin Tong, Pooja Khanna, Shelley A. H. Dixon, Michael P. Verzi, Gary L. Johnson, Michael L. Gatza

    Published 2021-04-01
    Get full text
    Article
  6. 6
    MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition

    MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition by Robert J. Mobley, Deepthi Raghu, Lauren D. Duke, Kayley Abell-Hart, Jon S. Zawistowski, Kyla Lutz, Shawn M. Gomez, Sujoy Roy, Ramin Homayouni, Gary L. Johnson, Amy N. Abell

    Published 2017-03-01
    Get full text
    Article
  7. 7
    Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors

    Synthesis and Evaluation of Novel 1,2,6-Thiadiazinone Kinase Inhibitors as Potent Inhibitors of Solid Tumors by Andreas S. Kalogirou, Michael P. East, Tuomo Laitinen, Chad D. Torrice, Kaitlyn A. Maffuid, David H. Drewry, Panayiotis A. Koutentis, Gary L. Johnson, Daniel J. Crona, Christopher R. M. Asquith

    Published 2021-09-01
    Get full text
    Article
  8. 8
    Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition

    Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Tr... by Timothy J. Stuhlmiller, Jon S. Zawistowski, Xin Chen, Noah Sciaky, Steven P. Angus, Sean T. Hicks, Traci L. Parry, Wei Huang, Ju Youn Beak, Monte S. Willis, Gary L. Johnson, Brian C. Jensen

    Published 2017-10-01
    Get full text
    Article
  9. 9
    Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

    Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition by Evan DuBose, Evan DuBose, Samantha M. Bevill, Samantha M. Bevill, Dana K. Mitchell, Noah Sciaky, Brian T. Golitz, Shelley A. H. Dixon, Steven D. Rhodes, Steven D. Rhodes, Steven D. Rhodes, Steven D. Rhodes, James E. Bear, James E. Bear, James E. Bear, Gary L. Johnson, Gary L. Johnson, Steven P. Angus, Steven P. Angus, Steven P. Angus, Steven P. Angus, Steven P. Angus

    Published 2024-05-01
    Get full text
    Article
  10. 10
    Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines

    Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines by Matthew E. Berginski, Madison R. Jenner, Chinmaya U. Joisa, Gabriela Herrera Loeza, Brian T. Golitz, Matthew B. Lipner, Jack R. Leary, Naim Rashid, Gary L. Johnson, Jen Jen Yeh, Shawn M. Gomez

    Published 2024-08-01
    Get full text
    Article
  11. 11
    Limited inhibition of multiple nodes in a driver network blocks metastasis

    Limited inhibition of multiple nodes in a driver network blocks metastasis by Ali Ekrem Yesilkanal, Dongbo Yang, Andrea Valdespino, Payal Tiwari, Alan U Sabino, Long Chi Nguyen, Jiyoung Lee, Xiao-He Xie, Siqi Sun, Christopher Dann, Lydia Robinson-Mailman, Ethan Steinberg, Timothy Stuhlmiller, Casey Frankenberger, Elizabeth Goldsmith, Gary L Johnson, Alexandre F Ramos, Marsha R Rosner

    Published 2021-05-01
    Get full text
    Article
  12. 12
    Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

    Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. by Matthew J Cooper, Nathan J Cox, Eric I Zimmerman, Brian J Dewar, James S Duncan, Martin C Whittle, Thien A Nguyen, Lauren S Jones, Sreerupa Ghose Roy, David M Smalley, Pei Fen Kuan, Kristy L Richards, Richard I Christopherson, Jian Jin, Stephen V Frye, Gary L Johnson, Albert S Baldwin, Lee M Graves

    Published 2013-01-01
    Get full text
    Article
  13. 13
    High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

    High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy by Chialin Cheng, Surya A. Reis, Emily T. Adams, Daniel M. Fass, Steven P. Angus, Timothy J. Stuhlmiller, Jared Richardson, Hailey Olafson, Eric T. Wang, Debasis Patnaik, Roberta L. Beauchamp, Danielle A. Feldman, M. Catarina Silva, Mriganka Sur, Gary L. Johnson, Vijaya Ramesh, Bruce L. Miller, Sally Temple, Kenneth S. Kosik, Bradford C. Dickerson, Stephen J. Haggarty

    Published 2021-08-01
    Get full text
    Article
  14. 14
    Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains

    Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains by Timothy J. Stuhlmiller, Samantha M. Miller, Jon S. Zawistowski, Kazuhiro Nakamura, Adriana S. Beltran, James S. Duncan, Steven P. Angus, Kyla A.L. Collins, Deborah A. Granger, Rachel A. Reuther, Lee M. Graves, Shawn M. Gomez, Pei-Fen Kuan, Joel S. Parker, Xin Chen, Noah Sciaky, Lisa A. Carey, H. Shelton Earp, Jian Jin, Gary L. Johnson

    Published 2015-04-01
    Get full text
    Article
  15. 15
    FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036

    FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 by Steven P. Angus, Timothy J. Stuhlmiller, Gaurav Mehta, Samantha M. Bevill, Daniel R. Goulet, J. Felix Olivares-Quintero, Michael P. East, Maki Tanioka, Jon S. Zawistowski, Darshan Singh, Noah Sciaky, Xin Chen, Xiaping He, Naim U. Rashid, Lynn Chollet-Hinton, Cheng Fan, Matthew G. Soloway, Patricia A. Spears, Stuart Jefferys, Joel S. Parker, Kristalyn K. Gallagher, Andres Forero-Torres, Ian E. Krop, Alastair M. Thompson, Rashmi Murthy, Michael L. Gatza, Charles M. Perou, H. Shelton Earp, Lisa A. Carey, Gary L. Johnson

    Published 2021-05-01
    Get full text
    Article
  16. 16
    Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

    Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. by Synodos for NF2 Consortium, Robert Allaway, Steve P Angus, Roberta L Beauchamp, Jaishri O Blakeley, Marga Bott, Sarah S Burns, Annemarie Carlstedt, Long-Sheng Chang, Xin Chen, D Wade Clapp, Patrick A Desouza, Serkan Erdin, Cristina Fernandez-Valle, Justin Guinney, James F Gusella, Stephen J Haggarty, Gary L Johnson, Salvatore La Rosa, Helen Morrison, Alejandra M Petrilli, Scott R Plotkin, Abhishek Pratap, Vijaya Ramesh, Noah Sciaky, Anat Stemmer-Rachamimov, Tim J Stuhlmiller, Michael E Talkowski, D Bradley Welling, Charles W Yates, Jon S Zawistowski, Wen-Ning Zhao

    Published 2018-01-01
    Get full text
    Article
  17. 17
    Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.

    Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. by Long-Sheng Chang, Janet L Oblinger, Abbi E Smith, Marc Ferrer, Steven P Angus, Eric Hawley, Alejandra M Petrilli, Roberta L Beauchamp, Lars Björn Riecken, Serkan Erdin, Ming Poi, Jie Huang, Waylan K Bessler, Xiaohu Zhang, Rajarshi Guha, Craig Thomas, Sarah S Burns, Thomas S K Gilbert, Li Jiang, Xiaohong Li, Qingbo Lu, Jin Yuan, Yongzheng He, Shelley A H Dixon, Andrea Masters, David R Jones, Charles W Yates, Stephen J Haggarty, Salvatore La Rosa, D Bradley Welling, Anat O Stemmer-Rachamimov, Scott R Plotkin, James F Gusella, Justin Guinney, Helen Morrison, Vijaya Ramesh, Cristina Fernandez-Valle, Gary L Johnson, Jaishri O Blakeley, D Wade Clapp, Synodos for NF2 Consortium

    Published 2021-01-01
    Get full text
    Article

Search Tools: